Appointments: Lilly, Kiadis, Pliant, Alma, NeuroVia and Nektar Therapeutics

This week's roundup includes a handful of promotions by Eli Lilly, and various board and high-level appointments by companies including Kiadis Pharma, Aeterna Zentaris, Dermavant Sciences and Pliant Therapeutics.

Eli Lilly & Co. has promoted Josh Smiley to senior vice president and chief financial officer (CFO); he will also become a member of Lilly's executive committee. Derica Rice, Lilly's current CFO, will retire at the end of the year. Myles O'Neill has been promoted to senior vice president and president of manufacturing operations and will join Lilly's executive committee. Aarti Shah, senior vice president and chief information officer, has been appointed executive officer and will join Lilly's executive committee. These appointments will be effective January 1, 2018. Dan Skovronsky has been promoted to senior vice president for science and technology and president of Lilly Research Labs and will also become a member of Lilly's executive committee – effective June 1, 2018. Maria Crowe, Lilly's president of manufacturing operations, and Jan Lundberg, executive vice president for science and technology and president of Lilly Research Labs, will both be retiring from the company.

The International Society for Cellular Therapy (ISCT) has named Queenie Jang CEO. Jang has been an external consultant for ISCT...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Executives On The Move

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

More from Leadership

An Activist Investor Makes A Play For Pfizer

 

Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>